This trial is evaluating whether CALM Breathing will improve 2 primary outcomes and 15 secondary outcomes in patients with Respiratory Aspiration. Measurement will happen over the course of 3 months.
This trial requires 50 total participants across 2 different treatment groups
This trial involves 2 different treatments. CALM Breathing is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are not being studied for commercial purposes.
Respiratory aspiration can be cured with early treatment including intravenous steroids, which is extremely effective and minimally toxic. However, aspiration with prolonged symptoms or recurrence is difficult to cure. Aggressive aspiration treatment can also fail because of persistent bacterial infection of the esophageal mucosa and the underlying muscular tunic as well as chronic aspiration of solid food. Therefore, the best approach is to find a solution for all these elements.
Some of respiratory aspiration may result from factors other than the patient's breathing function. The most common causes of respiratory aspiration relate to diseases or disorders with the tongue and pharynx. Other causes of respiratory aspiration often do not change the patient's breathing status and may be less harmful. Some of this risk can be minimized by a regular exercise program and proper oral care including a proper diet.
The majority of patients admitted to the intensive care unit received some treatment of respiration. Most of this was in the form of oxygen supplementation, with a lower use of noninvasive ventilation. Patients who received such treatment had a lower risk of death. Nevertheless, most patients who received noninvasive ventilation were intubated, and a large percentage required tracheal surgery. Findings from a recent study from the study suggest that intensive care unit physicians have underestimated the need for noninvasive ventilation, and their administration should be intensified.
This article presents the various diseases that can cause respiratory aspiration in children and describe the treatment of the disorders which are associated with this complication. The treatment of respiratory aspiration consists of aspiration of the fluid, with the aid of a suction tip or forceps, if necessary. The presence of a nasogastric tube is necessary in most cases, especially when there is a severe inflammatory reaction resulting from the aspiration and when the amount of fluid is very large. A chest X-ray is recommended in all cases of patients with respiratory aspiration.
The common finding is the inability of a patient to speak, due to obstruction of the throat. Other symptoms include cough, hoarseness, and difficulty in breathing. Sometimes, it is not so easy to detect respiratory aspiration, so the patient can be told to breathe deeply, inhale deeply, and then exhale deeply repeatedly so that they don't pass out. Furthermore, a medical exam should be undertaken to examine the mouth, trachea, diaphragm, and lungs of the patient. If possible, a CT scan should be done of the upper or lower part of the chest to look at the lungs.
Asthma was reported in about 40,000 out of 526,000 (7.0%) people during the period studied. Rarer conditions such as aspiration of gastric contents, gastric outlet obstruction, and ingestion of sharp objects were reported much more rarely; in about 300 to 500 per year. The reported incidence of aspiration of gastric contents varies considerably between studies, with estimates ranging from 3.6 to 7.5 per 1000 persons/year for people aged 65 years or more. The incidence of aspiration of gastric contents increases with age, from 0.9 per 1000 persons/ year at age 10 to about 1.0 per 1000 persons/year at age 95 years, or 3.8–4.
To increase the participation of critically ill, ventilator-dependent patients in clinical trials, physicians may need to engage these patients in clinical trials, and clinical trial protocols must be developed to ensure that the patients can benefit from such trials.
In patients admitted for emergency intubation, the most common cause of aspiration was coughing, reported in 64% of patients. The next most common causes were vomiting, reported in 35% of patients; and sedation, reported in 7%. There was almost equal frequency of upper and lower respiratory tract aspiration. When compared to published in-hospital mortality rates of respiratory aspiration, our patient population may have been over-represented.
There are disparities in the rate of aspirated food and fluid between different age ranges. In children younger than 25 months, food items and fluid items are most commonly aspirated. As this age bracket is the most critically vulnerable, targeted education is needed to reduce risk and improve outcome.
In our experience, patients with recurrent respiratory aspiration have a higher probability of developing aspiration pneumonia, and have a poor outcome despite adequate treatment. Early identification of asphyxiation and the use of prophylactic interventions for aspiration are essential to prevent asphyxiation related complications in patients with recurrent respiratory infection.
The use of calm breathing as a therapeutic method has been found to reduce anxiety, improve digestion and decrease gastrointestinal symptoms. n\nCaveman is an internationally renowned, brand of calm breathing instrument manufactured in California. Caveman, which is based in New Zealand, is a manufacturer of meditation instruments named, ‘Power Breathing’. \n\nThe Power Breathing Caveman is a brand of calm breathing instrument manufactured by Caveman which features sound, fragrance, and light frequencies. The Breathing Power program was created in 2003 and includes instruments and instruction manuals available to be downloaded at Caveman’s website which cover basic and advanced meditation strategies.
There are only 2 clinical studies on Calm Breathing published to date. Those studies did not report any long-term outcome data. There is only one long-term study of Calm Breathing in a clinical setting. A randomized, controlled trial with long-term outcome data.